Clinical Trials Logo

Clinical Trial Summary

This research will be carried out to determine the effect of walking exercises performed using a behavioral change model on symptom severity and quality of life in patients with Atrial Fibrillation.


Clinical Trial Description

Unique value of the project: Atrial fibrillation (AF) is one of the cardiovascular (CV) problems with a significant disease burden associated with stroke, for both patients and healthcare providers worldwide. Worldwide, AF is the most common sustained cardiac arrhythmia in adults, with an estimated prevalence ranging between 2% and 4%. In our country, this rate is between 1.25% and 1.4%. Patients with AF have a significantly poorer health-related quality of life compared with both healthy individuals and those with other cardiovascular diseases. This has been reported to be due to the various symptoms that AF patients may experience, such as fatigue, palpitations, dyspnea, sleep difficulties, chest discomfort, and psychosocial distress, as well as anxiety related to treatments and potential complications. An important step in AF management in AF guidelines is the optimization of cardiovascular and comorbidity and the identification and management of comorbidities, cardiometabolic risk factors, and unhealthy lifestyle factors to achieve this. As a lifestyle change in AF management, modifiable factors that may pose a risk for all cardiovascular disease (CVD) and AF are emphasized. Obesity and effective weight control, blood pressure control, increased physical activity and implementation strategies to achieve other risk factor modification, care pathways and education are the topics covered in this context. Exercise is a modifiable lifestyle factor that can affect AF risk both before and after AF onset. However, the recommended frequency, duration, and intensity of exercise in particular affect AF patients in different ways. The need to provide additional benefit to the current medical treatment is increasing day by day, and it is generally accepted that this benefit can only be achieved by changing the lifestyle of individuals and the continuity of this behavior change. The recommendation of the guidelines for AF patients is that they should focus on lifestyle change. Again in the guidelines, the success of nurse-led studies in AF patient management is a remarkable finding. According to the behavior change model, by evaluating the abilities and opportunities of the individual, by providing motivation under the leadership of the nurse, behavioral change can be targeted in the individual and self-monitoring and self-management of the individual can be realized in the long term. Regulating nutrition and weight control, reducing and managing alcohol intake, controlling high blood pressure and increasing physical activity, and maintaining behavior change with the support and motivation of nurses will be beneficial in AF patients to make lifestyle changes in AF patients. Although there are studies on physical activity in the AF patient group in the literature, no similar study has been found in our country. In addition, studies are insufficient in terms of creating evidence, and it is emphasized that more studies are needed. For this purpose, it is planned to conduct a nurse-led intervention study based on a behavioral change model in order to encourage physical activity, which is one of the subtitles of lifestyle change, in adults with AF. Method: The project was planned as a prospective, single-blind, randomized controlled experimental type. The research will be carried out in Konya Necmettin Erbakan University Meram Medical Faculty Hospital Cardiology Department between March - October 2022. In determining the sample size, based on the studies in the literature, considering possible losses, and with 95% confidence and 80% test power, the minimum number of samples in each group was determined as 39 and a total of 78. In the collection of study data, the application steps of the Behavior Change Model and Behavior Change Wheel will be discussed first. Patient identification form, Short Form 36 (SF 36), University of Toronto Atrial Fibrillation Severity Scale (AFSS), Walk Tracking Chart and Pedometer (Pedometer) will be used as data collection tools. Management: Data will be collected by the assistant researcher at the beginning of the study, at the 4th and 12th weeks, in the new service building of the Necmettin Erbakan University Meram Medical Faculty Hospital, in the echocardiography laboratory doctor's room. In the preliminary application of the research, a questionnaire will be applied to 10 participants. In addition, to test the step counting accuracy of the pedometers according to the walking style, 5 participants will be visually counted and confirmed by the assistant researcher while walking at their own pace in the closed corridor. Application - When the implementation phase of the research begins, the purpose of the research will be explained and written/verbal consent will be obtained by interviewing individuals with AF sent by a cardiology specialist at the Necmettin Erbakan University Meram Medical Faculty Hospital Cardiology Clinic or outpatient clinic. Consent will be taken in the echocardiography laboratory doctor's room, where data are collected. Individuals who agree to participate in the research will be evaluated in terms of inclusion and exclusion criteria. - As part of current clinical practice, all participants' blood pressure (BP), height and weight will be measured by the assistant researcher at study initiation. The patient identification form, the Toronto AF Symptom Severity Scale and Short Form 36 (SF-36) will be evaluated by interview method at baseline. - Afterwards, an interview will be held by the assistant researcher about the lifestyle changes that are effective in all CV diseases and the health benefits of regular physical activity. Participants will be informed about the study and their written consent will be obtained. - Participants included in the intervention group during the implementation phase of the study will be told that physical activity will start with 10-15 minutes initially, and then continue until participants reach a duration of 30 or 60 minutes, 3 times a week. Participants will be instructed that the goal is to exceed the previous number of steps each time. - Participants will be informed that if participants feel fatigue or palpitations throughout the day, participants can exercise the next day. - If participants have trouble/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. In addition to the controls of the participants with ongoing symptoms, the study will be carried out under the supervision of a cardiologist throughout the study. - In order to ensure regular follow-up and control of the participants, a pedometer will be given and an explanation will be given about its use, and the participants will be asked to mark them on the walking tracking chart. After each exercise, the assistant researcher will explain to the participants how to keep a record. - The initial step count value will be recorded as the number of steps recorded on the first day the participant used the pedometer. - Participants will be instructed to put on the pedometer before walking and not to take it off during the walk. It will be emphasized that rhythmic walking is important for the pedometer to count correctly. - Phone calls will be made once a week in order to motivate the participants, and participants will be informed that participants can call the assistant researcher for consultation when needed. - Participants in the control group will receive standard clinical care. - BP measurement, body mass index (BMI), Toronto AF Symptom Severity Scale and Short Form 36 (SF-36) scales will be evaluated by the assistant researcher at the 4th week and at the end of the 12th week in the experimental and control groups. - In addition, the number of steps recorded continuously in the experimental group will be evaluated for analysis, taking into account the last measurements of the 4th and 12th weeks. Widespread effect: Studies have shown that physical activity increases the quality of life, exercise capacity, heart rate control, peak maximum oxygen consumption (VO2 max) value, and reduces symptoms in AF patients. General population studies show that mild to moderate physical activity is primarily and secondarily protective against AF. Given the well-defined effects of prolonged exercise on the risk of AF, it has been reported that the optimal exercise interval for adults may be 20 minutes of aerobics, walking or cycling, 3 to 5 times per week. However, achieving less than recommended levels of physical activity was associated with a reduced risk of mortality compared to inactive patients, suggesting that even below recommended levels of physical activity, it is better than nothing for secondary prevention of AF. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05189691
Study type Interventional
Source Necmettin Erbakan University
Contact Ayse UÇAR, MSC
Phone +905335506412
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date March 1, 2022
Completion date October 25, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04115735 - His Bundle Recording From Subclavian Vein
Recruiting NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A
Completed NCT03313167 - Screening for Atrial Fibrillation (AF)-Potential Patients to Increase AF Detection Rate
Active, not recruiting NCT04544397 - Outcomes of Second Generation Laser Balloon Ablation for Atrial Fibrillation
Completed NCT02923414 - Comparison of High Versus Escalating Shocks in Cardioverting Atrial Fibrillation N/A
Recruiting NCT04850508 - Validation of the Advisor HD Grid Mapping Catheter in Atrial Fibrillation Ablation
Recruiting NCT04590898 - Peri-device Leakage Closure After LAAO
Completed NCT03593486 - Low-Level EMF Stimulation for Paroxysmal Atrial Fibrillation N/A
Active, not recruiting NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Recruiting NCT05080712 - Progression of Atrial Fibrillation in the Young
Recruiting NCT04096547 - Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
Terminated NCT04076917 - Assessment of the Utility of BIOMONITOR to Identify Atrial Fibrillation (AF) in Ablation Candidates Using Precise AF Detection
Active, not recruiting NCT03259373 - IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation N/A
Not yet recruiting NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)